Please login to the form below

Not currently logged in
Email:
Password:

US recall of four children's products

Blacksmiths Brands has announced the recall of four children's products in the PediaCare line in the US

Blacksmiths Brands has announced the recall of four children's products in the PediaCare line in the US.

The voluntary recall comes after consultation with the US Food and Drug Administration (FDA) in what Blacksmiths Brands described as a 'precautionary step'.

The products had all been manufactured at the McNeil Consumer Healthcare Fort Washington, Pennsylvania, which has been temporarily shut down following an FDA inspection that found serious violations of the agency's good manufacturing practice requirements. McNeil Consumer Healthcare is a subsidiary of Johnson & Johnson.

The products involved in the recall are PediaCare Multi-Symptom Cold 4oz, PediaCare Long Acting Cough 4oz, PediaCare Decongestant 4oz and PediaCare Allergy and Cold 4oz.

In a statement, the company said: "the recall was not initiated as a result of any consumer reports of adverse events and no consumer complaints have been received about the safety or purity of the products."

Blacksmiths Brands have however advised customers who own any of the recalled products to dispose of them.

Peter Man, chairman and CEO of the company, said: "We're taking this voluntary step because protecting consumers and maintaining their trust are essential to our company's core values."

New arrangements for the manufacture of the recalled products have been made, with shipments expected to resume in July.

1st June 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics